CAPR Capricor Therapeutics Inc PHARMACEUTICAL PREPARATIONS Best Pharmaceutical Stocks 2026 →

Capricor Therapeutics (CAPR) Stock: Buy, Sell, or Hold?

$8.47
-1.06 (-11.12%) ▼
5d: -14.01% 30d: +26.23% 90d: +19.63%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (43%)
Quality Score
28/100
Position
SLIGHTLY HIGH
30-Day Fair Range
$6.16 – $9.06
Position: SLIGHTLY HIGH
Forward P/E & Valuation
-6.7x CHEAP
vs 133.6x historical avg
Wall Street Target
$27.25
+185.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$7.15 / $11.23
Trend: Strong Downtrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: CAPR is down 14.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Smart Money Distribution

Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →

Signal fired Nov 6, 2026 at $9.01 · last confirmed Nov 16, 2026

Strength: 8.0/10

Get Alerted When CAPR Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

In-depth Analysis How we analyze

Valuation Analysis: CAPR is currently trading at $8.47, which is considered slightly high relative to its 30-day fair value range of $6.16 to $9.06. From a valuation perspective, the stock is trading at a discount (Forward PE: -6.7) compared to its historical average (133.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, CAPR is in a strong downtrend. Immediate support is located at $7.15, while resistance sits at $11.23. Short-term momentum is weak, with the stock down 11.1% recently.

Market Sentiment: CAPR scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $27.25 (+185.9%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position SLIGHTLY HIGH
Historical Trading Range $6.16 - $9.06
Company Quality Score 28/100 (SELL)
Volume Confirmation HIGH
Confidence Score 42.9%

Trading Range & Key Levels

30-Day Trading Range $6.16 - $9.06
Current vs Trading Range SLIGHTLY HIGH
Support Level $7.15
Resistance Level $11.23
Current Trend Strong Downtrend
Technical data as of Nov 16, 2026

Protect Your Profits

Holding CAPR? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

Institutional Signals, 13F Whale Activity & Setup Structure

Quantitative Research Feed
Active Quantitative Risk Vetoes (1)
Attention Chase Risk: msg spike z=2.6 (166 vs ~65/day), 5d move +19.1%
Phase & Gamma Walls CONSOLIDATION
Days in Phase: 56d (66% conf)
Put Wall / Support: $7 (3,715 OI)
Call Wall / Resist: $10 (11,595 OI)
Technical Setup Structure MONITORING
Absorption: Inactive (CMF 0.29)
Pullback / Drawdown: -73.0% from 52W High
Consolidation: Trending (ADX 33.6)

Quantitative Signal Breakdown

  • BEARISH: Weak technical setup (0/100)
  • BULLISH: High volume confirmation
  • BEARISH: Downward momentum (-11.1%)
  • BULLISH: Trading 185.9% below Wall St target ($27.25)
  • BULLISH: Market expects only 0% annual growth - appears undervalued
  • WARNING: Composite score 28/100 in the bottom quintile — this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) -6.65
Wall Street Target $27.25 (+185.9%)
Revenue Growth (YoY) -7.9%
PE vs Historical -6.7 vs 133.6 CHEAP
Share CAPR Analysis

Share this live CAPR analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (CAPR)

Bullish 13 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
12 msgs
24h retail stream
Last Tracked
Nov 16, 2026
Daily AI digest
AI Retail Discussion Summary: Capricor's DMD therapy faces a make-or-break FDA decision, with Oppenheimer bullish on approval and significant upside for the stock. Savara's lung disease drug is also in the spotlight.
Key Retail Themes: FDA approval prospects Impact of Oppenheimer's optimistic view
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 16, 2026 2:11 PM ET
Data refreshes hourly during market hours. Next update: 3:11 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for CAPR.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
CYTK
Cytokinetics Inc
STRONG BUY
22 analysts
$109 60 BUY
INSM
Insmed Inc
STRONG BUY
24 analysts
$194 33 SELL
MDGL
Madrigal Pharmaceuticals…
STRONG BUY
19 analysts
$689 48 HOLD
CRNX
Crinetics Pharmaceutical…
STRONG BUY
17 analysts
$86 46 HOLD
CRSP
Crispr Therapeutics AG
BUY
23 analysts
$85 49 HOLD

Advanced CAPR Option Strategies

Professional options setups generated by AI based on today's CAPR price and gamma walls.

Iron Condor Bull Call Bear Put Collar
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals